Leuven (BELGIUM), Madrid (SPAIN) – August 8, 2012 – TiGenix (NYSE Euronext: TIG),
the European leader in cell therapy, announced today the completion of patient enrollment
in the Company’s Phase IIa study of Cx611, a suspension of expanded allogeneic adult
stem cells, in rheumatoid arthritis. The Phase IIa clinical trial is a 53-subject, multicenter,
placebo-controlled study in 3 cohorts with different dosing regimens, designed to assess
safety, feasibility, tolerance, and optimal dosing. The study is being conducted at 23
centers. The Company believes that this clinical trial can set the stage not only for the
further development of Cx611 in RA, but also in a wide range of other autoimmune
disorders.

“In addition to the primary endpoints of safety and optimal dosing, we expect this trial to
yield a first indication of the duration of the efficacy of Cx611 in this very difficult patient
population: the enrolled patients have previously failed to respond to at least two
biologicals,” said Eduardo Bravo, CEO of TiGenix. “In the trial patients are treated with three
injections of Cx611. The six-month follow-up without further dosing should provide us with a
truly meaningful result. This is the most advanced stem cell therapy trial in RA in the world,
and completing the enrollment on time confirms our leadership position in the field. We
anticipate reporting the results of the study no later than April 2013.”
About Cx611 for rheumatoid arthritis.

Cx611 is a suspension of expanded allogeneic adult stem cells derived from human
adipose (fat) tissue (expanded Adipose derived Stem Cells or ‘eASCs’) that is delivered
through intra-venous injection for the treatment of rheumatoid arthritis. The objective of the
Phase IIa trial is to determine safety, feasibility, tolerance, and optimal dosing. This
multicentre, placebo-controlled study has enrolled 53 patients, divided in 3 cohorts with
different dosing regimens. There are 23 centers open and the company expects the final
results to be available in the first half of 2013.